Kypha’s Post

As our understanding of the role of complement in cancer expands, we can begin to see new connections and treatment opportunities For example, a new review highlights the context dependent role of complement in cancer and the potential for stratifying patients based on complement status to appropriately target complement alone or in combination with other anti-cancer therapies to enhance efficacy. You can read the review here: https://lnkd.in/ecbp3_cT What might help examine these interactions more closely? Accurate complement activation testing during drug development to both maximize benefits and limit risks. Find out more about Kypha’s expertise at https://lnkd.in/eyDT-dVc #complement #bispecifics #immunotherapies #diagnostics #complementdiagnostics #immunemonitoring #cancertherapeutics

The Cancer Drug Development Forum (CDDF) live webinar on EU Clinical Trial Regulations is next week https://lnkd.in/dJCMnFZp Tarec Christoffer El-Galaly Stéphanie Kromar EORTC - European Organisation for Research and Treatment of Cancer #Cancer #CancerResearch #Webinar #ClinicalTrial #Medicine #Health #Oncology #OncoDaily

We know that the survival window for HGG patients can be short due to the limited treatment advancements over the past few decades. That's why we created 3D Predict™ Glioma. This test offers a new way forward by identifying individual responses to standard-of-care treatments like temozolomide (TMZ) before treatment begins. It will show with 98% certainty which chemo will (or won't) kill a patient's cancer cells so different treatment possibilities may be considered — whether it's: 🩺 An alternative chemotherapy, 🏥 clinical trial, or 🏡 no treatment at all. See how our functional precision oncology test prospectively identifies patients' response to TMZ in this recent study: go.nature.com/3XrcTpF #Kiyatec #3DPredict #FunctionalPrecisionOncology #Temozolomide #RadiationTherapy #OncologyInnovation #StandardOfCare #SurvivalRate #PatientAdvocacy #PatientSupport #PatientCare #QualityOfLife

There is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. Claudin18.2 (CLDN18.2) is a new biomarker with a targeted therapy to treat gastric/GEJ cancer and can improve the outcome for patients. To learn how CLDN18.2 testing can enhance care and help your patients, visit: https://lnkd.in/gdhNUNyk #Gastric #Adenocarcinoma #Claudin182

#CQISundayRead Cancer drug shortages and high-cost cancer medications can limit the ability of patients with cancer to receive the medications they need, learn more about how Michigan Oncology Quality Consortium (MOQC) is working with programs to reduce medication waste. https://ow.ly/Yxah50Su9sq

Join Parexel's regulatory experts, all former regulators, for an in-depth 90-minute educational workshop where we explore the transformative potential of ADCs in cancer therapy. 💡 In this session, you'll gain insights into: 🔬 The development and characterization of ADCs in the non-clinical stage ⚙️ Critical considerations and challenges in CMC (Chemistry, Manufacturing, and Controls) 💊 Exciting clinical developments shaping the future of cancer treatment Don't miss out on this opportunity to expand your knowledge of the multidimensional aspects of ADCs and their potential to revolutionize #cancer care. 📅 Date & Time: Sept. 26, 2024 | 11:00 AM BST 🎟️ Register Now: https://lnkd.in/d6C9Tss8 #Healthcare #ClinicalResearch #ClinicalTrials #ADC #CancerTherapy #AntibodyDrugConjugates #ParexelBiotech #Webinar

Adjuvant therapy and combination therapy leverage the strengths of different treatments to provide a more robust and comprehensive approach to cancer care. By targeting multiple pathways, reducing resistance, lowering dosages, and addressing tumor heterogeneity, these strategies offer improved efficacy and outcomes compared to mono-therapy. Below is an example!

This represents a significant milestone for R in regulatory submissions. This achievement may mark a shift in the pharmaceutical industry towards more transparent and efficient data analysis tools, improving accuracy and consistency in data processing while reducing costs. It is a positive indicator for the credibility and acceptance of R and open-source software in regulatory environments and sets a foundation for future R-based submissions.

👉Introducing Abione: a breakthrough in prostate cancer treatment. Our 250mg tablets, containing Abiraterone acetate, target and inhibit androgen production, slowing the growth and spread of cancer cells. Not just a treatment, but a beacon of hope for patients.🤍✨ #Abione #ProstateCancer #HealthcareInnovation #DDK #DDKHealthcare #HealthcareSpecialist

Ovarian Cancer Treatment Market Growth and Development Insight - Size, Share, Growth, and Industry Analysis https://lnkd.in/eUSVunRJ #marketanalysis #marketresearch #marketresearchreports #businessintelligence